Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) Announces Submission of U.S and EU Regulatory Applications for Soliris (Eculizumab) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 09, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Soliris, Eculizumab, Refractory Generalized Myasthenia Gravis, Gmg, Fda, European Medicines Agency
